Stock Track | Personalis Soars 5.34% Pre-Market on Medicare Coverage for Breast Cancer Test

Stock Track11-10

Shares of Personalis (PSNL) surged 5.34% in pre-market trading on Monday following a significant announcement regarding Medicare coverage for its breakthrough cancer detection technology.

The company revealed that its ultrasensitive Minimal Residual Disease (MRD) test for breast cancer has been approved for Medicare coverage. This development marks a crucial milestone for Personalis, potentially expanding the accessibility and adoption of its innovative diagnostic tool.

The Medicare coverage decision is likely driving investor optimism, as it could lead to increased revenue streams for Personalis. MRD tests are critical in cancer treatment, helping oncologists detect tiny amounts of cancer cells remaining after treatment, which can indicate the risk of recurrence. With breast cancer being one of the most common cancers worldwide, this coverage decision opens up a substantial market opportunity for Personalis.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1169515864?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 22:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1169515864","market":"us","top_or_hot":-1,"title":"Stock Track | Personalis Soars 5.34% Pre-Market on Medicare Coverage for Breast Cancer Test","media":"Stock Track","content":"<p>Shares of Personalis (PSNL) surged 5.34% in pre-market trading on Monday following a significant announcement regarding Medicare coverage for its breakthrough cancer detection technology.</p>\n\n<p>The company revealed that its ultrasensitive Minimal Residual Disease (MRD) test for breast cancer has been approved for Medicare coverage. This development marks a crucial milestone for Personalis, potentially expanding the accessibility and adoption of its innovative diagnostic tool.</p>\n\n<p>The Medicare coverage decision is likely driving investor optimism, as it could lead to increased revenue streams for Personalis. MRD tests are critical in cancer treatment, helping oncologists detect tiny amounts of cancer cells remaining after treatment, which can indicate the risk of recurrence. With breast cancer being one of the most common cancers worldwide, this coverage decision opens up a substantial market opportunity for Personalis.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Personalis Soars 5.34% Pre-Market on Medicare Coverage for Breast Cancer Test</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Personalis Soars 5.34% Pre-Market on Medicare Coverage for Breast Cancer Test\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-10 22:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Personalis (PSNL) surged 5.34% in pre-market trading on Monday following a significant announcement regarding Medicare coverage for its breakthrough cancer detection technology.</p>\n\n<p>The company revealed that its ultrasensitive Minimal Residual Disease (MRD) test for breast cancer has been approved for Medicare coverage. This development marks a crucial milestone for Personalis, potentially expanding the accessibility and adoption of its innovative diagnostic tool.</p>\n\n<p>The Medicare coverage decision is likely driving investor optimism, as it could lead to increased revenue streams for Personalis. MRD tests are critical in cancer treatment, helping oncologists detect tiny amounts of cancer cells remaining after treatment, which can indicate the risk of recurrence. With breast cancer being one of the most common cancers worldwide, this coverage decision opens up a substantial market opportunity for Personalis.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PSNL","symbol_name":"Personalis","start_time":0,"source_url":"","article_id":"1169515864","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1169515864","pubTimestamp":1762784059,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Personalis (PSNL) surged 5.34% in pre-market trading on Monday following a significant announcement regarding Medicare coverage for its breakthrough cancer detection technology.  The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PSNL":"Personalis"},"translate_title":"个股追踪|Personalis因乳腺癌检测医保覆盖盘前飙升5.34%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PSNL":1},"content_text":"Shares of Personalis (PSNL) surged 5.34% in pre-market trading on Monday following a significant announcement regarding Medicare coverage for its breakthrough cancer detection technology.\nThe company revealed that its ultrasensitive Minimal Residual Disease (MRD) test for breast cancer has been approved for Medicare coverage. This development marks a crucial milestone for Personalis, potentially expanding the accessibility and adoption of its innovative diagnostic tool.\nThe Medicare coverage decision is likely driving investor optimism, as it could lead to increased revenue streams for Personalis. MRD tests are critical in cancer treatment, helping oncologists detect tiny amounts of cancer cells remaining after treatment, which can indicate the risk of recurrence. With breast cancer being one of the most common cancers worldwide, this coverage decision opens up a substantial market opportunity for Personalis.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1169515864","isCrawlerRequest":true}